Drug Profile
HIV vaccine (TBC-3B) - Therion Biologics
Alternative Names: DNA prime/MVA boost vaccine - Therion; multigenic DNA/MVA prime/boost vaccine - Therion; Recombinant MVA-fowlpox HIV-1 vaccine - Therion; Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B); TBC-3BLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA); Therion Biologics
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 06 Feb 2008 Pharmacodynamics data from a phase I trial in HIV-1 infections presented at the 15th Conference on Retroviruses and Opportunistic Infections (CROI-2008)
- 23 Feb 2006 Data presented at the 13th Conference on Retroviruses and Opportunistic Infections (CROI-2006) have been added to the Viral Infections pharmacodynamics and immunogenicity sections
- 22 Aug 2003 This programme is still in active development